Contact Us
About
Our Company
Management Team
Board of Directors
Scientific Advisors
Product Candidates
Overview
HONEDRA® (formerly CLBS12)
OLOGO™ (CLBS14)
CLBS16
CLBS119
CLBS201
Technology
Overview
CD34+ Cell Technology
Publications
Investors & News
Overview
Events
Press Releases
Media Coverage
Company Fact Sheet
Corporate Presentation
Analyst Coverage
SEC Filings
Corporate Governance
Disclosures
Stock Information
FAQs
Active Clinical Trials
FREEDOM (CLBS16)
HONEDRA® (formerly CLBS12)
Caladrius Biosciences CEO outlines key objectives for its cardiovascular programs in 2020
January 15, 2020
For link to original source, please
click here
.
January 15, 2020 January 15, 2020